Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).
Carné
Xavier
X
Servei de Farmacologia Clínica, Unitat d'Avaluació, Suport i Prevenció, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Catalonia, Spain. xcarne@clinic.ub.es
Cruz
Núria
N
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004335:Drug and Narcotic Control; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D013450:Sulfones / Q000009:adverse effects*; D014481:United States
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib